November 21, 2024
Biofidelity today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all guideline-recommended genes for non-small cell lung cancer (NSCLC) patients in both DNA and RNA from tissue and blood within two days, benefitting patients by enabling earlier treatment decisions.
November 14, 2024
Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer (NSCLC) biomarkers in both DNA and RNA from tissue and blood.
October 17, 2024
Lee Anderson joins Biofidelity to expand the adoption of Aspyre Lung, a completely new category of molecular diagnostic that fulfills an acute unmet clinical need for people with non-small cell lung cancer and the clinicians who treat them.
April 12, 2024 Genomeweb
Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types with Aspyre Lung.
April 12, 2024 Cambridge Independent
Biofidelity’s successful $24 million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing Aspyre Lung genomic testing protocol.
April 05, 2024 Business North Carolina
Biofidelity, a genomic technology company with headquarters in the Research Triangle Park, has raised $24 million from investors in a new round of funding.
